Considering that CD47 is a marker that is highly expressed in cancer cells and interacts with SIRPα to prevent their own phagocytosis, this pathway can be inhibited through anti-CD47 or anti-SIRPα therapy leading to more phagocytosis of cancer cells (92). Here, SIRPA is linked to cancer.